Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Bladder Cancer

NCT01938573 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01938573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01938573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Bladder Cancer
Lead sponsor
University of Washington
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2013
Completion date
August 18, 2016
Enrollment
21 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent bladder carcinoma, stage ii bladder cancer, stage iii bladder cancer, stage iv bladder cancer